Focused search for science

Curated, credible results

4Sciences helps users find science-focused information, products, and tools. Built by search architects and domain specialists, the platform combines multiple indexes, specialized ranking algorithms, and AI systems to return relevant, credible science content. Use the site to search literature, news, vendors, data, and practical resources. Part of the 4SEARCH network of topic specific search engines.

Why India's Deep-Tech Needs Engineers Who Can Invent New Tests

Oct 27, 2026 | Updated 12:05 PM GMT+5:30 Aule Space, a Bengaluru startup, keeps a room as dark as its engineers can make it. The company scouted for a special cloth that soaks up almost all the light that falls on it. In the middle of the room sits a mock-up of a satellite, lit by a lamp that plays the part of the sun. Aule uses the room to test the cameras and algorithms its spacecraft will rely on to navigate in orbit, under light as harsh as they will meet in space. The lamp came from an unlikely source. The only supplier with a light that met Aule's specifications was a company that rents lighting to film crews. "They were asking us what movie are we shooting," says Jay Panchal, Aule's co-founder and chief executive. "But we had to explain that this is our sun." The room exists because of what Aule wants to do in space. Communication satellites circle about 36,000 kilometres above…

1,751 words
More in Fields and Topics

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

SAN FRANCISCO and SUZHOU, China, Oct. 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that a New Indication Application for sintilimab in combination with Nolgileucel injection (GC101) has been accepted for review by the China National Medical Products Administration (NMPA). The application is proposed to be sintilimab in combination with Nolgileucel Injection (GC101) for the treatment of patients with unresectable or metastatic melanoma whose disease has progressed following at least two lines of prior systemic therapy, including PD-1 antibody therapy. This would be the 11th indication for sintilimab, further consolidating its position as a cornerstone…

1,042 words4 outlets
More in Biology, Genetics and Medicine

How going outside in nature could ease stress

(Aging Untold) — There is something about nature that makes us feel instantly connected. For the Tomlinson family, spending time outdoors is a daily routine. “Nature makes me feel happy and excited when I always get around it because it makes me feel like I’m at home,” said Gibbs Tomlinson, who enjoys spending time in nature. “See the sun come through the trees and being able to put a shadow on a leaf, the fish glistening in the creek, and it just makes you feel wholesome,” Brent Tomlinson, Gibbs’ father, said. Research shows nature could ease symptoms of depression, stress and ADHD. Aging Untold expert and gerontologist “Sam” Cradduck said human history was not built around pavement or concrete. “Human history wasn’t built in a concrete jungle. It wasn’t built around pavement. It was built around nature. And we are natural beings that need to connect back to fresh air, to the earth, to…

327 words6 outlets
More in Research and Discoveries

Agendia Unveils Clinical Validation of AI-Driven Digital Pathology Approach

The investigational AI-driven digital assay demonstrated high concordance with MammaPrint results in the prospective RASTER cohort of 372 early-stage breast cancer patients with a median follow-up of 10.3 years "AI has been part of Agendia's scientific foundation from the beginning and this study represents its continued evolution," said Dr. Laura van 't Veer. "For the first time, we are presenting our work exploring whether the biological information represented by MammaPrint can be recognized through AI applied to routinely generated pathology images." The investigational digital assay demonstrated a high concordance with MP (r = 0.954), classifying 49% of patients as D-High and 51% as D-Low. Patients classified as D-Low had a 10-year breast cancer-specific survival (BCSS) rate of 98.1%, compared to 86.7% for those classified as D-High (HR 0.12, p < 0.0001). In the estrogen…

192 words2 outlets
More in Technology and Tools